Replies to post #8017 on Algernon Pharmaceuticals Inc (AGNPF)

[shell3]

CEO claimed July/August

[Money $hot]

Sir, I am not attempting to jump the line here, but if you are asking when will patients start being dosed with NP-120 Ifenprodil, my understanding is May 8, 2020 is the start of PH2 clinical trial in South Korea. IMO, Chris Moreau (CEO) makes that crystal clear in the update from yesterday. Please see the update here:

Start at the 3:53 min/sec mark of video

The CEO states more than once in the interview that everything is on a "compressed" timeline.

NP-120 Ifenprodil is already an approved drug in South Korea for other indications.

COVID-19 - First Patient Dosing is imminent!

Faster Than A Speeding Bullet



Just 1 opinion,

/////AMG

$AGNPF

[medchem]

Thanks to the other moderators for responding, quicker than I could.

What I will add to their responses:

There are two things going on here...

1) We have existing drug

2) We are making more drug

So, for point 1:

We have enough drug in hand that we can supply the Phase 2 trial in South korea

So, for point 2:

We hired a chemical company in the USA to not only make more Ifenprodil for us but also look into making it in a more streamlined fashion.

Additional point:

We are going to secure IP on a novel formulation for IV use.

The implications of this go beyond our trials. If others want to use it by IV, they will be going through us.